Clinical trial · Interventional
Long-acting G-CSF for Febrile Neutropenia
Long-acting Granulocyte Colony Stimulating Factor for the Prevention Febrile Neutropenia in Epithelial Ovarian Cancer: A Phase 3 Randomized Control Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer. Patients are randomized into study group and control group. In study group, patients accept long-acting G-CSF 48 hours from the chemotherapy. While the control group accept regular treatment rather than long-acting G-CSF. The primary end is the incidence of FN in every course of chemotherapy. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adverse Event | — | UNRESOLVED | — |
| Colony Stimulating Factors | — | UNRESOLVED | — |
| Cost-effectiveness | — | UNRESOLVED | — |
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
| Febrile Neutropenia | — | UNRESOLVED | — |
| Myelosuppression Adult | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| long-acting granulocyte colony stimulating factor | Drug | — | UNRESOLVED |
| Short-term granulocyte colony stimulating factor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Study group
- description
- Patients in study group accept long-acting granulocyte colony stimulating factor 48 hours from the chemotherapy and regular interventions for myelosuppression.
- interventionNames
- Drug: long-acting granulocyte colony stimulating factor
- Drug: Short-term granulocyte colony stimulating factor
- type
- ACTIVE_COMPARATOR
- label
- Control group
- description
- Patients in control group only accept regular interventions for myelosuppression rather than long-acting granulocyte colony stimulating factor.
- interventionNames
- Drug: Short-term granulocyte colony stimulating factor
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Willing to accepted debulking surgeries and adjuvant chemotherapy * Good performance status * Aged 18 years or older * Signed an approved informed consents * No immunosuppressive disease Exclusion Criteria: * Not meeting all of the inclusion criteria
References
Publications (1)
- DERIVEDLi L, Ma S, Wu M, Tan X, Zhong S, Lang J. The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study. BMJ Support Palliat Care. 2019 Dec;9(4):373-380. doi: 10.1136/bmjspcare-2019-001862. Epub 2019 Aug 29. PMID 31467066